EUVIMEDEUVIMED entdecken
Crossref

Increasing the time‐to‐freezing for clinical apheresis plasma meets quality specifications

Kelly M Winter iD, Rachel G Webb, Eugenia Mazur, Sue Ismay, Dimitra Marinakis, Denese C Marks iD

Vox Sanguinis · 2023

DOI: 10.1111/vox.13532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Kelly M Winter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia. Hauptthemen laut MEDLINE: von Willebrand Factor, Blood Component Removal. Die Arbeit nennt 12 Literaturangaben. Gefördert von: Australian Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives In Australia, the vast distances between blood collection centres and processing facilities make it challenging to align supply with demand. Increasing the time to freezing for clinical plasma beyond 6 h would alleviate supply issues. This study aimed to determine the quality of clinical apheresis plasma frozen within 12 h of collection. Materials and Methods Apheresis plasma ( n = 20) collected at donor centres was immediately transported to a blood processing facility, stored at 26°C and sampled aseptically at 6, 8 and 12 h post collection. Frozen samples were thawed, and coagulation factors (F) II, V, VII, VIII and XIII, von Willebrand factor (vWF) and fibrinogen were measured using a coagulation analyser.

Results

FVIII concentrations declined in plasma frozen at 6, 8 and 12 h post collection (1.22 ± 0.27, 1.21 ± 0.25 and 1.16 ± 0.24 IU/mL, respectively) but not significantly ( p = 0.3338). Importantly, all components met the FVIII specification (>0.7 IU/mL) for clinical plasma. Fibrinogen concentrations were stable from 6 to 12 h ( p = 0.3100), as were vWF concentrations ( p = 0.1281). Coagulation factors II, V, VII and XIII were not significantly different ( p > 0.05 for all factors).

Conclusion

Clinical apheresis plasma can be frozen within 12 h of collection, allowing collections from donor centres further from processing centres and increasing supply.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand FactorBlood Component RemovalHumansFreezingBlood PreservationTime FactorsBlood Coagulation FactorsFibrinogenFactor VIII

Stichwörter der Autor:innen

apheresis plasmacoagulation factor VIIItime to freeze

Substanzen

von Willebrand FactorBlood Coagulation FactorsFibrinogenFactor VIII

Autor:innen und Institutionen

  • Research and Development, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia.
  • Manufacturing and Logistics, Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia.
  • Manufacturing and Logistics, Australian Red Cross Lifeblood, West Melbourne, Victoria, Australia.
  • Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.

ORCID-Profile: Kelly M Winter, Denese C Marks

Förderung

  • Australian Government

Zitieren

APA

Winter, K. M., Webb, R. G., Mazur, E., Ismay, S., Marinakis, D., & Marks, D. C. (2023). Increasing the time‐to‐freezing for clinical apheresis plasma meets quality specifications. Vox Sanguinis. https://doi.org/10.1111/vox.13532

Vancouver

Winter KM, Webb RG, Mazur E, Ismay S, Marinakis D, Marks DC. Increasing the time‐to‐freezing for clinical apheresis plasma meets quality specifications. Vox Sanguinis. 2023. doi:10.1111/vox.13532

BibTeX
@article{Winter2023,
  author = {Winter, Kelly M and Webb, Rachel G and Mazur, Eugenia and Ismay, Sue and Marinakis, Dimitra and Marks, Denese C},
  title = {Increasing the time‐to‐freezing for clinical apheresis plasma meets quality specifications},
  journal = {Vox Sanguinis},
  year = {2023},
  doi = {10.1111/vox.13532}
}
Kostenlos starten →